Intra-cellular therapies provides corporate update and reports third quarter 2019 financial results

Intra-cellular therapies provides corporate update and reports third quarter 2019 financial results.q3 loss per share $0.63.q3 earnings per share estimate $-0.80 -- refinitiv ibes data.intra-cellular - cash, cash equivalents and investment securities totaled $255.4 million at sept 30, 2019, compared to $347.5 million at dec 31, 2018.

ITCI Ratings Summary

ITCI Quant Ranking